Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.
2.
3.

A Chinese Immigrant Paradox? Low Coronary Heart Disease Incidence but Higher Short-Term Mortality in Western-Dwelling Chinese Immigrants: A Systematic Review and Meta-Analysis.

Jin K, Ding D, Gullick J, Koo F, Neubeck L.

J Am Heart Assoc. 2015 Dec 18;4(12). pii: e002568. doi: 10.1161/JAHA.115.002568.

4.

An Assay of Measuring Platelet Reactivity Using Monoclonal Antibody against Activated Platelet Glycoprotein IIb/IIIa in Patients Taking Clopidogrel.

Joo SJ, Choi JH, Kim SY, Kim KS, Kim YR, Kang SH.

Korean Circ J. 2015 Sep;45(5):378-85. doi: 10.4070/kcj.2015.45.5.378. Epub 2015 May 8.

5.

CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome.

Liu J, Nie XY, Zhang Y, Lu Y, Shi LW, Wang WM.

Chin Med J (Engl). 2015 Aug 20;128(16):2183-8. doi: 10.4103/0366-6999.162515.

6.

Thromboelastography for monitoring platelet function in unruptured intracranial aneurysm patients undergoing stent placement.

Yang H, Li Y, Jiang Y, Lv X.

Interv Neuroradiol. 2015 Feb;21(1):61-8. doi: 10.15274/INR-2014-10094.

7.

State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.

Kumbhani DJ, Marso SP, Alvarez CA, McGuire DK.

Curr Cardiovasc Risk Rep. 2015 Jan;9:4.

8.

Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study.

Jiang W, Boyle SH, Ortel TL, Samad Z, Velazquez EJ, Harrison RW, Wilson J, Kuhn C, Williams RB, O'Connor CM, Becker RC.

Am Heart J. 2015 Apr;169(4):496-507.e1. doi: 10.1016/j.ahj.2014.12.002. Epub 2014 Dec 17.

9.

Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel.

Tang XF, Han YL, Zhang JH, Wang J, Zhang Y, Xu B, Gao Z, Qiao SB, Chen J, Wu Y, Chen JL, Gao RL, Yang YJ, Yuan JQ.

Chin Med J (Engl). 2015 Mar 20;128(6):774-9. doi: 10.4103/0366-6999.152611.

10.

Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects.

Cleator JH, Duvernay MT, Holinstat M, Colowick NE, Hudson WJ, Song Y, Harrell FE, Hamm HE.

J Pharmacol Exp Ther. 2014 Oct;351(1):33-43. doi: 10.1124/jpet.114.215616. Epub 2014 Jul 22.

11.

Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome.

Viswanathan GN, Marshall SM, Balasubramaniam K, Badimon JJ, Zaman AG.

Thromb Res. 2014 May;133(5):880-5. doi: 10.1016/j.thromres.2014.01.033. Epub 2014 Feb 1.

12.

Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study.

Darling CE, Sala Mercado JA, Quiroga-Castro W, Tecco GF, Zelaya FR, Conci EC, Sala JP, Smith CS, Michelson AD, Whittaker P, Welch RD, Przyklenk K.

BMJ Open. 2014 Jan 17;4(1):e003883. doi: 10.1136/bmjopen-2013-003883.

13.

No effect of clopidogrel activity or cessation on vascular function or markers of inflammation.

Kuzniatsova N, Balakrishnan B, Lip GY, Blann AD.

Int J Angiol. 2012 Dec;21(4):195-200. doi: 10.1055/s-0032-1328777.

14.

Personalized antiplatelet therapy: state of the art.

Gurbel PA, Jeong YH, Tantry US.

JRSM Cardiovasc Dis. 2012 Sep 24;1(6). pii: cvd.2012.012015. doi: 10.1258/cvd.2012.012015. Review.

15.

Pharmacogenomics of anti-platelet and anti-coagulation therapy.

Fisch AS, Perry CG, Stephens SH, Horenstein RB, Shuldiner AR.

Curr Cardiol Rep. 2013 Jul;15(7):381. doi: 10.1007/s11886-013-0381-3. Review.

16.

Mean platelet volume reproducibility and association with platelet activity and anti-platelet therapy.

Shah B, Valdes V, Nardi MA, Hu L, Schrem E, Berger JS.

Platelets. 2014;25(3):188-92. doi: 10.3109/09537104.2013.793794. Epub 2013 Jun 20.

17.

Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?

Perry CG, Shuldiner AR.

J Hum Genet. 2013 Jun;58(6):339-45. doi: 10.1038/jhg.2013.41. Epub 2013 May 23. Review.

18.

Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation.

Berger JS, Becker RC, Kuhn C, Helms MJ, Ortel TL, Williams R.

Thromb Haemost. 2013 Jan;109(1):85-92. doi: 10.1160/TH12-03-0202. Epub 2012 Dec 6.

19.

High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study.

Chirumamilla AP, Maehara A, Mintz GS, Mehran R, Kanwal S, Weisz G, Hassanin A, Hakim D, Guo N, Baber U, Pyo R, Moses JW, Fahy M, Kovacic JC, Dangas GD.

JACC Cardiovasc Imaging. 2012 May;5(5):540-9. doi: 10.1016/j.jcmg.2011.12.019.

20.

Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses.

Rowley JW, Finn AV, French PA, Jennings LK, Bluestein D, Gross PL, Freedman JE, Steinhubl SR, Zimmerman GA, Becker RC, Dauerman HL, Smyth SS; 2011 Platelet Colloquium Participants.

Circ Cardiovasc Interv. 2012 Apr;5(2):296-304. doi: 10.1161/CIRCINTERVENTIONS.111.965426. Review. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk